No abstract

The safety and immunogenicity of the two-dose injections of the CoronaVac vaccine (Sinovac Life Sciences) have been reported in Phase 1 and 2 trials. 1,2 After the approval of CoronaVac by the Indonesian government, the coronavirus disease 2019 (COVID-19) vaccination program was launched in January 2021, with the first administration batch targeted towards healthcare workers. However, published data regarding the humoral immune response after Cor-onaVac vaccination in subjects not included in clinical trials are scarce. Therefore, this report aims to evaluate the effectiveness of two doses of CoronaVac vaccine by investigating the level of total Ig anti-receptor binding domain (RBD) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a retrospective study carried out using nonprobability sampling. Subjects were included based on the fulfillment of the following criteria: (1) healthy volunteers; (2) healthcare workers receiving Cor-onaVac vaccine between January and March 2021; (3) has received two doses of CoronaVac (at a 2-week interval [0 and 14 days], with each dose containing inactivated SARS-CoV-2 virus 3 mcg [600 SU] in 0.5 ml); (4) has had a measurement of the Ig anti-RBD quantified by Elecsys Anti-SARS-CoV-2 S (Roche, cut-off value ≥ 0.8 U/ml) after the second dose of CoronaVac vaccine. The Elecsys Anti-SARS-CoV-2 S serology assay is a quantitative electrochemiluminescence immunoassay (ECLIA) utilizing a recombinant protein representing the RBD of the spike antigen and captures predominantly anti-SARS-CoV-2 IgG. 3,4 This study was approved by the Faculty of Medicine and Health Science, Maulana Malik Ibrahim State Islamic University of Malang ethics committee (Ref. No. 023/EC/KEPK-FKIK/2021), and informed consent was obtained from all subjects.The Ig anti-RBD measurement time was varied, ranging from 7 to 49 days after the second dose of the CoronaVac vaccine. Subjects were hence grouped according to the time of Ig anti-RBD measurement. The Ig anti-RBD level between groups was statistically analyzed either by one-way analysis of variance (ANOVA) or paired/ unpaired t-test using SPSS version 25 with a significance threshold of p < 0.05, and all figures were generated using the Graphpad PRISM.Initially, a total of 131 subjects, consisting of 59 male (45%) and 72 female (55%) healthcare workers (mean age overall, 35.

Infeksi paru akibat Nontuberculous Mycobacteria (NTM) dan Mycobacterium tuberculosis (MTB) dapat memberikan gambaran klinis yang serupa sehingga berpotensi menyebabkan kesalahan diagnosis dan terapi. Pemeriksaan Multiplex PCR (MPCR)-Universal Lateral Flow Assay (ULFA) merupakan pemeriksaan berbasis molekuler untuk mendeteksi gen rpoB, IS1660 dan mtp40 yang dapat digunakan untuk membedakan infeksi NTM dari infeksi TB. Tujuan:  Mendapatkan gambaran infeksi NTM menggunakan MPCR-ULFA pada penderita terduga TB paru. Metode: Penelitian ini merupakan studi deskriptif dengan pendekatan potong lintang yang dilaksanakan sejak April sampai Juli 2019. Sebanyak 39 sampel sputum dari pasien terduga TB paru dari RSUD Kanjuruhan Kepanjen, Kabupaten Malang diperiksakan apusan BTA, GeneXpert dan MPCR-ULFA. Hasil: Sebanyak 5 sampel (12,8%) sputum dari pasien terduga TB paru terdeteksi sebagai NTM positif menggunakan pemeriksaan MPCR-ULFA. Empat dari lima sampel (80%) tersebut memiliki kesesuaian dengan hasil GeneXpert dan apusan BTA, yakni MTB negatif.  Pemeriksaan molekuler baik GeneXpert maupun MPCR-ULFA keduanya mendeteksi keberadaan gen rpoB dari Mycobacterium. Metode MPCR-ULFA mengamplifikasi 3 gen target sekaligus (IS1660, mtp40 dan rpoB) sehingga dapat mendeteksi infeksi NTM atau MTB. Simpulan: Prevalensi NTM pada pasien terduga TB paru di RSUD Kanjuruhan Kepanjen menggunakan MPCR-ULFA mencapai 12,8%. Sebanyak 80% dari NTM positif memiliki hasil pemeriksaan GeneXpert dan apusan BTA negatif.Kata kunci: GeneXpert, MPCR-ULFA, NTM, suspek TB paru